Intrathecal IgM Species as Potential Prognostic Biomarkers in Relapsing-Remitting Multiple Sclerosis

This retrospective study examined whether specific IgM antibody markers in cerebrospinal fluid could predict disease progression in 37 relapsing-remitting MS patients over up to 17 years. Patients with both oligoclonal IgM bands and anti-S-nitrosylated protein IgM showed more aggressive disease, while those lacking both markers had more benign outcomes, suggesting these biomarkers may help guide clinical management decisions.